US Edition
GSK Set for $500 Million Payment From mRNA Lawsuit Settlement
4 Articles
4 Articles
GSK Set for $500 Million Payment From mRNA Lawsuit Settlement
CureVac NV has settled a long-running patent dispute over mRNA vaccines with Pfizer Inc. and BioNTech SE in the US, which will see CureVac’s former collaborator GSK Plc receive as much as $500 million and 1% of royalties from future vaccine sales.
GSK Receives $370 Million Settlement Payment in mRNA Patent Dispute with CureVac, Pfizer, and BioNTech
GSK has secured a $370 million upfront payment as part […] The post GSK Receives $370 Million Settlement Payment in mRNA Patent Dispute with CureVac, Pfizer, and BioNTech first appeared on GeneOnline News. The post GSK Receives $370 Million Settlement Payment in mRNA Patent Dispute with CureVac, Pfizer, and BioNTech appeared first on GeneOnline News.
15:46 To settle a patent dispute over mRNA vaccines, Germany's BioNTech is paying British pharmaceutical company GSK $370 million. This could amount to up to half a billion dollars.
Coverage Details
Bias Distribution
- 100% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
